Burlington, Massachusetts-based risk-benefit consultancy ParagonRx has appointed Dr Stephen Sun as its new chief medical officer.
Dr Sun was formerly a medical officer at US regulator the FDA and in his new role will provide regulatory and strategy advice on the optimal and safe use of new drugs and devices.
He began his pharmaceutical industry career at Organon, working in drug safety and medical knowledge management, before joining Alpharma as director of drug safety.
He was promoted to senior director of medical affairs and then after King Pharmaceuticals’ acquisition of Alpharma, Dr Sun served as King’s senior director of pharmacovigilance and risk management.
After gaining OTC experience at Reckitt-Benckiser, Dr Sun Sun joined the FDA as a medical officer, serving in the CDER Division of Risk Management and most recently in the Controlled Substances staff.
In his new role at ParagonRx, part of inVentiv Health, he will report directly to ParagonRx president Jeffrey Fetterman.
“The focus today is on enhanced pharmacovigilance, putting preventions in place before any regulatory body requires it,” Fetterman said. “Dr Sun’s FDA experience will enrich the guidance we offer clients to assure that active risk management is at the core of developing all new products and services.”